Aurinia Pharmaceuticals reports Q2 EPS 16c, consensus 15c

Reports Q2 revenue $70.0M, consensus $63.8M. As of June 30, 2025, Aurinia had cash, cash equivalents, restricted cash and investments of $315.1M vs. $358.5M at December 31, 2024. “We continue to see solid growth for Lupkynis, partially driven by the new 2024 American College of Rheumatology lupus nephritis treatment guidelines, which recommend the incorporation of drugs like LUPKYNIS into first-line therapy in order to preserve kidney function,” stated Peter Greenleaf, CEO. “Additionally, we are excited about the positive results from our Phase 1 study of aritinercept, a dual inhibitor of B cell-activating factor and a proliferation-inducing ligand. Aritinercept was well tolerated at all dose levels tested and single doses led to robust and long-lasting reductions in immunoglobulins. We look forward to initiating clinical studies in at least two autoimmune diseases in the second half of this year.”